Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

Phase 1

Terminated

• Conditions: Neoplasm; Lymphomas; Neoplasm Metastasis

• Registration Number: NCT00023166
• Lead Sponsor: Enzon Pharmaceuticals, Inc.

Brief Summary

Studies of PEG-paclitaxel have been terminated

Detailed Description

Not available

Study Timeline

• Study Start: 2001-05
• Study First Submitted: 2001-08-24
• Study First Submitted QC: 2001-08-25
• Study First Posted: 2001-08-27
• Study Completion: 2002-05
• Status Verified: 2004-03
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP